Xenoreactivity of human clonal mesenchymal stem cells in a major histocompatibility complex-matched allogeneic graft-versus-host disease mouse model

Cellular Immunology

Volumn 261, Issue 1, 2010, Pages 57-63

  Jeon, Myung Shin ^a   Lim, Hyun Ja ^a   Yi, Tac Ghee ^a   Im, Moon Whan ^a   Yoo, Hyun Seung ^b   Choi, Jung Hwa ^b   Choi, Eun Young ^b   Song, Sun U ^a  

^a Inha University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Clonal MSC; GVHD; IDO; IL 10; T cell

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; THERAPY EFFECT;

ANIMALS; CELLS, CULTURED; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INTERFERON-GAMMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 73849105297     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.11.001     Document Type: Article

References (40)

1. Friedenstein A.J., Gorskaja J.F., and Kulagina N.N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp. Hematol. 4 (1976) 267-274
2. Caplan A.I. Mesenchymal stem cells. J. Orthop. Res. 9 (1991) 641-650
3. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276 (1997) 71-74
4. Schwartz R.E., Reyes M., Koodie L., Jiang Y., Blackstad M., Lund T., Lenvik T., Johnson S., Hu W.S., and Verfaillie C.M. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J. Clin. Invest. 109 (2002) 1291-1302
5. Woodbury D., Schwarz E.J., Prockop D.J., and Black I.B. Adult rat and human bone marrow stromal cells differentiate into neurons. J. Neurosci. Res. 61 (2000) 364-370
6. Toma C., Pittenger M.F., Cahill K.S., Byrne B.J., and Kessler P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105 (2002) 93-98
7. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., and Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2002) 3838-3843
8. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., and Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
9. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., and Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75 (2003) 389-397
10. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A., and Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30 (2002) 42-48
11. Augello A., Tasso R., Negrini S.M., Cancedda R., and Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 56 (2007) 1175-1186
12. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., Shpall E.J., McCarthy P., Atkinson K., Cooper B.W., Gerson S.L., Laughlin M.J., Loberiza Jr. F.R., Moseley A.B., and Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11 (2005) 389-398
13. Li W.J., Chiang H., Kuo T.F., Lee H.S., Jiang C.C., and Tuan R.S. Evaluation of articular cartilage repair using biodegradable nanofibrous scaffolds in a swine model: a pilot study. J. Tissue Eng. Regen. Med. 3 (2009) 1-10
14. Liao W., Xie J., Zhong J., Liu Y., Du L., Zhou B., Xu J., Liu P., Yang S., Wang J., Han Z., and Han Z.C. Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke. Transplantation 87 (2009) 350-359
15. Yan H., and Yu C. Repair of full-thickness cartilage defects with cells of different origin in a rabbit model. Arthroscopy 23 (2007) 178-187
16. Itakura S., Asari S., Rawson J., Ito T., Todorov I., Liu C.P., Sasaki N., Kandeel F., and Mullen Y. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am. J. Transplant. 7 (2007) 336-346
17. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., and Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
18. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., Dini G., Egeler R.M., Bacigalupo A., Fibbe W., and Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008) 1579-1586
19. Uccelli A., Moretta L., and Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8 (2008) 726-736
20. Song S.U., Kim C.S., Yoon S.P., Kim S.K., Lee M.H., Kang J.S., Choi G.S., Moon S.H., Choi M.S., Cho Y.K., and Son B.K. Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes, differentiation potential, gene expression, and cytokine secretion. Stem Cells Dev. 17 (2008) 451-461
21. Horowitz M.M., and Bortin M.M. Current status of allogeneic bone marrow transplantation. Clin. Transpl. (1990) 41-52
22. O'Reilly R.J. Allogenic bone marrow transplantation: current status and future directions. Blood 62 (1983) 941-964
23. Spierings E., Brickner A.G., Caldwell J.A., Zegveld S., Tatsis N., Blokland E., Pool J., Pierce R.A., Mollah S., Shabanowitz J., Eisenlohr L.C., van Veelen P., Ossendorp F., Hunt D.F., Goulmy E., and Engelhard V.H. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood 102 (2003) 621-629
24. Choi E.Y., Yoshimura Y., Christianson G.J., Sproule T.J., Malarkannan S., Shastri N., Joyce S., and Roopenian D.C. Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility antigen dominates over all others. J. Immunol. 166 (2001) 4370-4379
25. Falkenburg J.H., and Willemze R. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. Best Pract. Res. Clin. Haematol. 17 (2004) 415-425
26. Rasmusson I., Ringden O., Sundberg B., and Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76 (2003) 1208-1213
27. Rasmusson I., Uhlin M., Le Blanc K., and Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J. Leukoc. Biol. 82 (2007) 887-893
28. Morandi F., Raffaghello L., Bianchi G., Meloni F., Salis A., Millo E., Ferrone S., Barnaba V., and Pistoia V. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells 26 (2008) 1275-1287
29. Saito T., Kuang J.Q., Bittira B., Al-Khaldi A., and Chiu R.C. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann. Thorac. Surg. 74 (2002) 19-24 discussion 24
30. Liechty K.W., MacKenzie T.C., Shaaban A.F., Radu A., Moseley A.M., Deans R., Marshak D.R., and Flake A.W. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat. Med. 6 (2000) 1282-1286
31. Choi E.Y., Christianson G.J., Yoshimura Y., Jung N., Sproule T.J., Malarkannan S., Joyce S., and Roopenian D.C. Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Blood 100 (2002) 4259-4265
32. Polchert D., Sobinsky J., Douglas G., Kidd M., Moadsiri A., Reina E., Genrich K., Mehrotra S., Setty S., Smith B., and Bartholomew A. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38 (2008) 1745-1755
33. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., Zhao R.C., and Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2 (2008) 141-150
34. Dazzi F., and Marelli-Berg F.M. Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells. Eur. J. Immunol. 38 (2008) 1479-1482
35. Sato K., Ozaki K., Oh I., Meguro A., Hatanaka K., Nagai T., Muroi K., and Ozawa K. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109 (2007) 228-234
36. Katz J.B., Muller A.J., and Prendergast G.C. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 222 (2008) 206-221
37. Min C.K., Kim B.G., Park G., Cho B., and Oh I.H. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant. 39 (2007) 637-645
38. Goldman J.M., Baughan A.S., McCarthy D.M., Worsley A.M., Hows J.M., Gordon-Smith E.C., Catovsky D., Batchelor J.R., Goolden A.W., and Galton D.A. Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet 2 (1982) 623-625
39. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., Marschall H.U., Dlugosz A., Szakos A., Hassan Z., Omazic B., Aschan J., Barkholt L., and Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (2006) 1390-1397
40. Zhao C.P., Zhang C., Zhou S.N., Xie Y.M., Wang Y.H., Huang H., Shang Y.C., Li W.Y., Zhou C., Yu M.J., and Feng S.W. Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. Cytotherapy 9 (2007) 414-426